DI
ALNY icon

Disciplined Investments’s Alnylam Pharmaceuticals ALNY Stock Holding History

Disciplined Investments’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-5
Closed -$950 – 167
2023
Q2 		$950 Buy
5
+2
+67% +$397 ﹤0.01% 990
2023
Q1 		$601 Sell
3
-1
-25% -$210 ﹤0.01% 1172
2022
Q4 		$951 Sell
4
-1
-20% -$213 ﹤0.01% 926
2022
Q3 		$1K Buy
5
+3
+150% +$572 ﹤0.01% 768
2022
Q2 		$0 Sell
2
-1
-33% -$142 ﹤0.01% 1237
2022
Q1 		$0 Buy
+3
New +$457 ﹤0.01% 1319

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Disciplined Investments's ALNY Position: Q3 2023 in Review

Disciplined Investments sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2023, closing a stake of 5 shares — an estimated $950 sold.

Disciplined Investments first reported a position in ALNY in Q1 2022 and held it in 6 quarters. The position peaked at $1K in Q3 2022. 453 funds tracked by Wall St. Rank hold ALNY as of Q3 2023.

  • Disciplined Investments reported no remaining Alnylam Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Disciplined Investments sold 5 Alnylam Pharmaceuticals shares in Q3 2023, an estimated $950.
  • Disciplined Investments first reported a position in Alnylam Pharmaceuticals in Q1 2022 and held it in 6 quarters.
  • Disciplined Investments's Alnylam Pharmaceuticals position peaked at $1K in Q3 2022.
  • 453 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2023.

Based on Disciplined Investments's 13F filing for Q3 2023, filed 14 Nov 2023.